The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an ...

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...

The FDA granted accelerated approval to mosunetuzumab (Lunsumio; Genentech), a CD20/CD3 bispecific T-cell engager administered as a subcutaneous injection for patients with relapsed or refractory ...

Cancer pain is a significant public health concern worldwide, necessitating effective management strategies. This study aimed to explore the effects of patient-controlled subcutaneous analgesia (PCSA) ...

BISHKEK, Dec 1 (Reuters) - OSCE election observers said on Monday that a weekend parliamentary election in Kyrgyzstan had been efficiently run, but stifled by a restrictive campaign environment and ...

According to Lilly, the single-injection, citrate-free, maintenance dose will be available in the US as a prefilled pen or prefilled syringe in early 2026. The Food and Drug Administration (FDA) has ...

Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting ...

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent protections expiring in 2028. The FDA has approved a subcutaneous version of ...